Skip to main content

Table 5 Stepwise regression analysis for incident diabetic patients after dialysis with 5-year survival rate, n = 335

From: Effect of anti-diabetic drugs in dialysis patients with diabetes: a nationwide retrospective cohort study

Variables Univariate Multivariate
HR (95% CI) P-value aHR (95% CI) P-value
Age > 60 years 2.52 (1.67–3.79)  < 0.001 2.35 (1.56–3.55)  < 0.001
Gender—male 1.40 (0.98–2.00) 0.068   
Anti-diabetic drug use
 OHA 1    
 Insulin 1.63 (1.14–2.33) 0.008 1.41 (0.98–2.02) 0.068
Region
 Northern 1    
 Central 1.23 (0.80–1.89) 0.900   
 Southern/Eastern 0.94 (0.63–1.52) 0.398   
Insured premium (NT$)
 < 15,840 1    
 15,840–25,000 0.78 (0.51–1.20) 0.254   
 > 25,000 0.87 (0.55–1.38) 0.543   
Urbanization
 Urban 1    
 Sub-urban 0.75 (0.50–1.12) 0.157   
 Rural 0.84 (0.47–1.62) 0.565   
Hospital characteristics
 Medical center 1.19 (0.81–1.76) 0.378   
 Region/others 1    
Number of admissions during the 12 months leading up to dialysis
 0–1 1    
 > 1 1.59 (1.05–2.43) 0.031   
Dialysis modality
 Peritoneal dialysis 1    
 Hemodialysis 1.24 (0.54–2.81) 0.614   
Comorbidity
 Hypertension 1.22 (0.85–1.75) 0.275   
 Hyperlipidemia 0.43 (0.23–0.81) 0.008 0.45 (0.24–0.85) 0.014
 Gout 0.85 (0.50–1.46) 0.557   
 Congestive heart failure 1.27 (0.85–1.89) 0.239   
 Cerebrovascular accident 2.03 (1.28–3.22) 0.003 2.04 (1.27–3.29) 0.003
 COPD 1.92 (1.18–3.14) 0.009 1.68 (1.03–2.76) 0.039
 Chronic liver disease 1.00 (0.47–2.15) 0.998   
 Malignancy 1.65 (0.98–2.80) 0.061   
ACEI/ARB use 0.68 (0.48–0.97) 0.033   
Lipid-lowering drugs use 0.50 (0.33–0.76) 0.001 0.66 (0.43–1.02) 0.060
  1. HR hazard ratio, CI confidence interval, aHR adjusted hazard ratio, OHA oral hypoglycemia agents, COPD chronic obstructive pulmonary disease, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers